Anteris Technologies Adjusts Timeline for Nasdaq Listing

2 min read | September 30, 2024 04:10 PM AEST | By Team Kalkine Media

Google News:

Anteris Technologies Adjusts Timeline for Nasdaq Listing — Image source: shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights

Anteris extends Nasdaq listing schedule.

Scheme meetings rescheduled to October or November 2024.

Focus remains on re-domiciliation and structural heart innovations.

Anteris Technologies Ltd (ASX:AVR) has announced a revised timeline for its planned Nasdaq listing and re-domiciliation to the United States. The structural heart company is still on track to complete these milestones within the current calendar year, though its scheme meetings and Extraordinary General Meeting (EGM), originally scheduled for October 4, 2024, have been deferred. New dates for these meetings are expected in October or November 2024.

The company's board continues to support the re-domiciliation process, highlighting that the benefits significantly outweigh any associated risks. Shareholders are encouraged to vote in favor of the share scheme, as the company progresses toward its goals.

About Anteris Technologies

Anteris Technologies, originally based in Australia, has a growing presence in the U.S., particularly in Minneapolis, a key MedTech hub. The company focuses on designing and commercializing innovative medical devices to address critical unmet clinical needs in structural heart disease.

The company’s flagship product, DurAVR®, is a transcatheter heart valve (THV) designed for treating aortic stenosis. Developed in collaboration with top cardiologists and cardiac surgeons, DurAVR® is the first transcatheter aortic valve replacement (TAVR) made from a single piece of bioengineered tissue. This advanced valve mimics the natural function of a healthy human aortic valve, aiming to deliver transformative outcomes for patients with heart disease.

Despite the extension in its Nasdaq listing timetable, Anteris remains focused on advancing its innovative medical solutions and strategic U.S. market positioning.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.